Our Strategy
Our strategy maximizes the power of Artificial Intelligence with a sector – based approach, involving biotech companies with a high – growth potential.
Stoneprime US algorithms identify the theoretical ideal entry – point for the biotech companies in our portfolio, evaluating the importance of each step of the FDA Approval Process.
The combination between Qualitative AI and Quantitative AI exploits 2 parallel input streams, to develop the purchase and the selling signal, that could also happen after the event.
Our inputs
Our Qualitative AI has many inputs to evaluate the development potential of Biotech companies:
MOLECULES
TRIALS
PAPERS
CONGRESS ABSTRACTS
INNOVATION INDEX
COMPETITORS
R&D DEPARTMENT
SCIENTIFIC BACKGROUND
AI conducts an evaluation of the trial that is not simply scientific, but also concerns the social consequences and then the market impact of any trial approval.
Our Quantitative AI finds the ideal entry point for the examined stock to be subject to a potential portfolio.
The conjunction between these two independent approaches gives rise to a unique signal of trading applied to our Biotech companies, producing buying and selling signals.
Our new AI, based on Large Language Models, will enable us to enhance the extraction of numerical data from textual data, providing further information about the potential of biotech companies.